$1.30
0.69% today
Nasdaq, Sep 12, 03:49 pm CET
ISIN
CA6823108759
Symbol
ONCY

Oncolytics Biotech Inc. Stock price

$1.31
+0.44 50.99% 1M
+0.70 113.84% 6M
+0.40 43.36% YTD
+0.37 38.62% 1Y
-0.12 8.39% 3Y
-0.32 19.63% 5Y
-4.23 76.34% 10Y
-23.49 94.72% 20Y
Nasdaq, Closing price Thu, Sep 11 2025
+0.00 0.00%
ISIN
CA6823108759
Symbol
ONCY
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$11.3m
Shares outstanding
97.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
29.6%
Return on Equity
-530.0%
ROCE
-231.3%
ROIC
-1,553.4%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-22.2m | $-45.3m
EBIT
$-22.4m | $-30.9m
Net Income
$-22.0m | $-22.5m
Free Cash Flow
$-17.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
15.1% | -81.5%
EBIT
15.1% | -22.1%
Net Income
-8.5% | 1.8%
Free Cash Flow
7.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
2.6%
Employees
28
Rev per Employee
$0.0
Show more

Is Oncolytics Biotech Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Oncolytics Biotech Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Oncolytics Biotech Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Oncolytics Biotech Inc. forecast:

Buy
75%
Hold
25%

Financial data from Oncolytics Biotech Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.97 8.97
19% 19%
-
- Research and Development Expense 13 13
12% 12%
-
-22 -22
15% 15%
-
- Depreciation and Amortization 0.28 0.28
10% 10%
-
EBIT (Operating Income) EBIT -22 -22
15% 15%
-
Net Profit -22 -22
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Oncolytics Biotech Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oncolytics Biotech Inc. Stock News

Neutral
PRNewsWire
4 days ago
In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.5x the current standard of care Translational data from multiple studies confirm pelareorep replication in CRC tumors and immune activation Company to define regulatory pathway and advance potential IST in KRAS mutant CRC patient population SAN DIEGO , Sept. 8, 2025 /PRNewswire...
Neutral
PRNewsWire
10 days ago
Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with multiple treatments Updated clinical data now account for over 300 gastrointestinal cancer patients, including patients from the GOBLET study, demonstrating pelareorep's potential as a platform therapy Intravenously administered pelareorep continues to show clinical benefit...
Neutral
PRNewsWire
15 days ago
SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, will participate in two investor conferences next month. CEO Jared Kelly will be meeting with institutional investors at the H.C.
More Oncolytics Biotech Inc. News

Company Profile

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Head office Canada
CEO Wayne Pisano
Employees 28
Founded 1998
Website www.oncolyticsbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today